- Home
- AVT vs ACAD Comparison
AVT vs ACAD Comparison
Compare AVT & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVT
- ACAD
- Stock Information
- Founded
- AVT 1921
- ACAD 1993
- Country
- AVT United States
- ACAD United States
- Employees
- AVT N/A
- ACAD N/A
- Industry
- AVT Electronic Components
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- AVT Technology
- ACAD Health Care
- Exchange
- AVT Nasdaq
- ACAD Nasdaq
- Market Cap
- AVT 4.3B
- ACAD 4.3B
- IPO Year
- AVT N/A
- ACAD 2004
- Fundamental
- Price
- AVT $53.64
- ACAD $24.76
- Analyst Decision
- AVT Sell
- ACAD Buy
- Analyst Count
- AVT 3
- ACAD 21
- Target Price
- AVT $49.00
- ACAD $29.30
- AVG Volume (30 Days)
- AVT 1.1M
- ACAD 1.9M
- Earning Date
- AVT 10-29-2025
- ACAD 11-05-2025
- Dividend Yield
- AVT 2.46%
- ACAD N/A
- EPS Growth
- AVT N/A
- ACAD 615.00
- EPS
- AVT 2.75
- ACAD 1.33
- Revenue
- AVT $22,200,754,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- AVT $5.51
- ACAD $14.01
- Revenue Next Year
- AVT $6.01
- ACAD $12.00
- P/E Ratio
- AVT $19.51
- ACAD $18.54
- Revenue Growth
- AVT N/A
- ACAD 14.41
- 52 Week Low
- AVT $39.22
- ACAD $13.40
- 52 Week High
- AVT $59.24
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- AVT 50.63
- ACAD 51.02
- Support Level
- AVT $51.90
- ACAD $23.34
- Resistance Level
- AVT $54.15
- ACAD $24.93
- Average True Range (ATR)
- AVT 1.04
- ACAD 0.83
- MACD
- AVT -0.07
- ACAD -0.18
- Stochastic Oscillator
- AVT 56.51
- ACAD 44.78
About AVT Avnet Inc.
Avnet Inc is a global distributor of electronic components, connecting suppliers of semiconductors and other components to a base of 2.1 million small- and mid-sized customers in 140 countries. Avnet is the third largest semiconductor distributor in the world, and the largest for European chip distribution. Avnet services all levels of electronics design and development, servicing engineers with design tools, test kits, and services alongside its high-volume distribution for final designs.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.